Study of Hepatic Responses in Patients Receiving Direct-acting Anti-HCV Drugs

Study Results

Results pending

The study team has not published outcome measurements, participant flow, or safety data for this trial yet. Check back later for updates.

Basic Information

Get a concise snapshot of the trial, including recruitment status, study phase, enrollment targets, and key timeline milestones.

Recruitment Status

COMPLETED

Total Enrollment

5 participants

Study Classification

OBSERVATIONAL

Study Start Date

2015-08-31

Study Completion Date

2018-07-10

Brief Summary

Review the sponsor-provided synopsis that highlights what the study is about and why it is being conducted.

This study is designed to obtain and store samples of serum and liver tissue in HCV (HepC Virus)-infected patients being treated with direct-acting antiviral (DAA) therapy, and to determine the effect of new DAA therapies on HCV-related responses in the liver and peripheral blood.

The introduction of new DAAs regimens that do not include IFN provides unique and novel opportunities to examine whether successful treatment-induced eradication of viral antigen results in reconstitution of T cell immunity. serum and liver tissue samples will be collected and stored in hopes of improving treatment and outcomes for future patients.

Related Clinical Trials

Explore similar clinical trials based on study characteristics and research focus.

Immune Monitoring of Hepatitis C Under DAA Therapy

NCT02904603

Hepatitis C

UNKNOWN

Response Guided Treatment With Direct Acting Anti-Viral Medications for Chronic HCV Infection

NCT03603327

Hepatitis C

COMPLETED NA

An Observational Study on Long-Term Persistence of Resistant Mutations And Durability of Sustained Virological Response in Patients With Chronic Hepatitis C Treated With Direct Acting Antiviral (DAA)- Containing Regimens

NCT01168856

Hepatitis C, Chronic

TERMINATED

Study Investigating Immunological Effects of Treatment for Chronic Hepatitis C Patients.

NCT00422838

Hepatitis C Liver Immunology +1 more

COMPLETED

Clinical Performance Evaluation of DxN HCV Assay

NCT03125408

Hepatitis C

TERMINATED

Detailed Description

Dive into the extended narrative that explains the scientific background, objectives, and procedures in greater depth.

This study is designed to obtain and store samples of serum and liver tissue in HCV-infected patients being treated with DAA therapy.

A liver biopsy will be performed pre-treatment for research reasons. A small liver sample that is not required for pathologic analysis will also be stored. Patients will undergo another liver biopsy at either 4 or 12 weeks after initiation of DAA therapy.

Any patients with HCV-related liver disease (age \> 18) will be considered for this study.

Patients will have a 120 ml blood draw for research purposes at baseline and 12 weeks after stopping DAA treatment along with a 60 ml blood draw at 2, 4, 8, and 12 weeks of treatment.

The liver biopsy at baseline and then either at 4 or 12 weeks will be examined using molecular techniques to measure transcription of key genes involved in the antiviral response.

Conditions

See the medical conditions and disease areas that this research is targeting or investigating.

Hepatitis C

Study Design

Understand how the trial is structured, including allocation methods, masking strategies, primary purpose, and other design elements.

Observational Model Type

COHORT

Study Time Perspective

PROSPECTIVE

Study Groups

Review each arm or cohort in the study, along with the interventions and objectives associated with them.

Patients who will have their second Liver biopsy at week 4

The 4 week time point is performed in lieu of the 12 week and the purpose of this time point is to evaluate earlier responses and transcriptional changes that might predict viral clearance or treatment failure in a subset of patients.

Liver Biopsy

Intervention Type PROCEDURE

patients will get a research liver biopsy pre-DAA treatment and either 4 or the standard 12 week time point. The liver biopsy is performed using standard protocol with ultrasound guidance.

Patients who will have their second Liver biopsy at week 12

Liver biopsies will be obtained at week 12 when most DAA treatments end in order to compare the hepatic responses induced or reduced by clearance of HCV

Liver Biopsy

Intervention Type PROCEDURE

patients will get a research liver biopsy pre-DAA treatment and either 4 or the standard 12 week time point. The liver biopsy is performed using standard protocol with ultrasound guidance.

Interventions

Learn about the drugs, procedures, or behavioral strategies being tested and how they are applied within this trial.

Liver Biopsy

patients will get a research liver biopsy pre-DAA treatment and either 4 or the standard 12 week time point. The liver biopsy is performed using standard protocol with ultrasound guidance.

Intervention Type PROCEDURE

Eligibility Criteria

Check the participation requirements, including inclusion and exclusion rules, age limits, and whether healthy volunteers are accepted.

Inclusion Criteria

* Signed informed consent
* Ages 18-70
* HCV-infected patients being treated with direct-acting antiviral (DAA) therapy.

Exclusion Criteria

* Pregnant women or females of childbearing potential that are not on contraception
* Institutionalized or mentally disabled persons
* Prisoners
* Unwilling or unable to provide informed consent
* Subjects who are HIV positive
* Anticipated inability to follow up
* Chronic anemia
* Platelet count \< 100 for liver biopsy patients who have documented fatty liver disease by ultrasound prior to enrollment
* Any patient with bleeding disorders or prolonged INR
* Abstinent or consuming less than two drinks of alcohol per day.
* Clinical hepatic decompensation (i.e., ascites, encephalopathy or variceal hemorrhage).

Minimum Eligible Age

18 Years

Maximum Eligible Age

70 Years

Eligible Sex

ALL

Accepts Healthy Volunteers

No